EVELO BIOSCIENCES
Evelo Biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. Monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. These new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. Monoclonal mi... crobials have the potential to fundamentally change traditional models of drug discovery and development. By finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, Evelo can improve the speed, cost and success of drug discovery and development. Evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. Evelo Biosciences was conceived and created within VentureLabs®, Flagship Pioneering’s institutional innovation foundry, and launched by Flagship in 2015.
EVELO BIOSCIENCES
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.evelobio.com
Total Employee:
51+
Status:
Active
Contact:
+1 617 577 0300
Email Addresses:
[email protected]
Total Funding:
281.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Bezoar Laboratories
Bezoar Laboratories is devoted to improving the health of humans, animals, and environment with innovative microbial solutions.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
PuraCath Medical
PuraCath Medical is dedicated to improving the quality of life for the dialysis patient by reducing infections.
Cogent Biosciences
Cogent Biosciences is a biopharmaceutical company that develops therapies for solid cancer tumors.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-07-12 | Epiva | Epiva acquired by Evelo Biosciences | N/A |
Investors List
Dementia Discovery Fund
Dementia Discovery Fund investment in Venture Round - Evelo Biosciences
Mayo Clinic Ventures
Mayo Clinic Ventures investment in Series B - Evelo Biosciences
Flagship Pioneering
Flagship Pioneering investment in Series B - Evelo Biosciences
GV
GV investment in Series B - Evelo Biosciences
Celgene
Celgene investment in Series B - Evelo Biosciences
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - Evelo Biosciences
Flagship Pioneering
Flagship Pioneering investment in Series A - Evelo Biosciences
Key Employee Changes
Official Site Inspections
http://www.evelobio.com Semrush global rank: 2.04 M Semrush visits lastest month: 10.27 K
- Host name: 132.36.196.104.bc.googleusercontent.com
- IP address: 104.196.36.132
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Evelo Biosciences" on Search Engine
Evelo Biosciences Announces Top-Line Results From its Phase 2 …
CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo” or the “Company”), a clinical stage biotechnology company …See details»
Evelo Biosciences Provides Clinical and Business Updates
CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of …See details»
Evelo Biosciences - Crunchbase Company Profile
Evelo Biosciences is a biotechnology company that develops oral biologics for small intestinal axis with systemic therapeutic effects. Cambridge, Massachusetts, United …See details»
Leadership Team - Evelo
Chun Zhang, Ph.D. Chief Technical Operations and Quality Officer. View Biography. Evelo is a small company thinking big for patients. Our aim is to create massive positive …See details»
Evelo Biosciences - Funding, Financials, Valuation
Jul 12, 2016 $397M. in funding over 8 rounds. Their latest funding was raised on Jul 10, 2023 from a Post-IPO Equity round. Evelo Biosciences is registered under the ticker …See details»
Evelo Biosciences | LinkedIn
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic...See details»
Evelo Biosciences Announces Key 2022 Strategic …
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ …See details»
Evelo Biosciences Presents New Preclinical Data for Anti-Tumor …
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) a clinical stage biotechnology company developing a new modality of …See details»
SEC Filing Announcement - Evelo
View Evelo’s SEC filings Direct all inquiries to [email protected]See details»
Evelo Bio Shutdown Follows a Series of Microbiome Therapy Trial ...
Nov 22, 2023 Evelo Biosciences is shutting down, a move that follows a series of clinical trial setbacks, a corporate downsizing, and the failure to secure additional financing to …See details»
Evelo Biosciences Announces $25.5 Million Private Placement
CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of …See details»
Flagship-founded Evelo finds dissolution is only viable option
Nov 22, 2023 Evelo Biosciences is dissolving. One month after starting a search for strategic alternatives, the Flagship Ventures-backed microbiome biotech has found its …See details»
Evelo keeps CEO, lets go of 48 employees after ph. 2 fail - Fierce …
Feb 1, 2023 Evelo Biosciences’ lead asset has flunked a phase 2 trial in eczema after an unusually high placebo response rate was reported in the first three of four cohorts. The …See details»
Evelo Biosciences Announces Second Quarter Financial Results …
Dec 31, 2022 News Release Details. Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights. August 14, 2023 at 7:30 AM EDT. …See details»
Evelo Biosciences - Contacts, Employees, Board Members, …
Organization. Evelo Biosciences. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 13. …See details»
Evelo Biosciences | CipherBio
Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects. These cells in the …See details»
Evelo Biosciences to Report Fourth Quarter and Full Year 2022 …
CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of …See details»
Evelo Biosciences Provides Clinical and Business Updates
CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of …See details»
evlo-20231120 - SEC.gov
Nov 20, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware: 001-38473: 46-5594527 (State or other jurisdiction of incorporation or …See details»
evlo-20230707 - SEC.gov
On July 7, 2023, Evelo Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein …See details»